Vertex Pharmaceuticals Incorporated (VRTX)
Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors
Vertex Pharmaceuticals (VRTX) reached $464.2 at the closing of the latest trading day, reflecting a -1.73% change compared to its last close.
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Vertex Pharmaceuticals (VRTX) Rises As Market Takes a Dip: Key Facts
Vertex Pharmaceuticals (VRTX) reached $452.16 at the closing of the latest trading day, reflecting a +1.56% change compared to its last close.
Vertex Pharmaceuticals Incorporated (VRTX) Presents at American Diabetes Association (ADA) 85th Scientific Sessions Conference Transcript
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) American Diabetes Association (ADA) 85th Scientific Sessions Conference June 20, 2025 8:15 PM ET Company Participants James Markmann - Corporate Participant Michael Rickels - Corporate Participant Felicia Pagliuca - Corporate Participant Susie Lisa - Senior Vice President of Investor Relations Conference Call Participants Adam Ferrari - JPMorgan Chase & Co, Research Division Bryan Russell Dollinger - Leerink Partners LLC, Research Division Dina Elmonshed - Jefferies LLC, Research Division Jarwei Fang - Unidentified Company Liisa Ann Bayko - Evercore ISI Institutional Equities, Research Division Malcolm Hoffman - BMO Capital Markets Equity Research Mohit Bansal - Wells Fargo Securities, LLC, Research Division Terence C. Flynn - Morgan Stanley, Research Division a division of S&P - Unidentified Company Susie Lisa Thanks for your patience.
Here's Why Vertex Pharmaceuticals (VRTX) Fell More Than Broader Market
In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $440.87, denoting a -1.68% move from the preceding trading day.
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Goldman Sachs 46th Annual Global Healthcare Conference Call June 10, 2025 2:40 PM ET Company Participants David M. Altshuler - Executive VP & Chief Scientific Officer Reshma Kewalramani - CEO, President & Director Conference Call Participants Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division Salveen Jaswal Richter Good afternoon, everyone.
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.
VRTX Stock Down as Q1 Sales of New Drugs Miss Expectations
Sales from VRTX's new drugs, Casgevy, Alyftrek and Journavx, in Q1 fell short of investor expectations.
VRTX's Q1 Earnings Lag Estimates, 2025 Revenue View Tightened
Vertex reports weaker-than-expected first-quarter 2025 results. The company tightens its total revenue guidance for 2025.
Vertex Pharmaceuticals Incorporated (VRTX) Q1 2025 Earnings Call Transcript
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Q1 2025 Earnings Conference Call May 5, 2025 4:30 PM ET Company Participants Susie Lisa - SVP, IR Reshma Kewalramani - CEO, President & Director Stuart Arbuckle - EVP & COO Duncan McKechnie - COO Charles Wagner - EVP & CFO Conference Call Participants Geoffrey Meacham - Citibank Jessica Fye - JPMorgan Salveen Richter - Goldman Sachs Tazeen Ahmad - Bank of America Merrill Lynch Evan Seigerman - BMO Capital Markets Michael Yee - Jefferies Liisa Bayko - Evercore ISI Eliana Merle - UBS David Risinger - Leerink Gena Wang - Barclays Operator Good day, and welcome to the Vertex Pharmaceuticals First Quarter 2025 Earnings Call. [Operator Instructions].
